3 results
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A in patients with prodromal or mild Alzheimer*s disease (AD), ages 50*80, who are amyloid positive by cerebrospinal fluid (CSF) or amyloid positron…
1. To assess the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's disease (AD).2. To assess the pharmacokinetics (PK) of ABBV-8E12 in subjects with early AD.The exploratory objectives of this study are:• To…
Primary• To evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first line treatment) as measured by Progression Free Survival (PFS) in subjects with Claudin (CLDN) 18.2-positive,…